News: Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

111.00EUR
5 Feb 2016
Change (% chg)

€-2.85 (-2.50%)
Prev Close
€113.85
Open
€113.80
Day's High
€114.05
Day's Low
€111.00
Volume
42,069
Avg. Vol
41,339
52-wk High
€120.20
52-wk Low
€87.50

Search Stocks
Select another date:

Tue, Jan 26 2016

BRIEF-Biomerieux: Biofire's Filmarray gets CE marked

* Biofire's Filmarray meningitis/encephalitis panel gets CE marked Source text for Eikon: Further company coverage: (Gdynia Newsroom)

CORRECTED-BRIEF-Biomerieux FY sales of 1,965 mln euro, up 15.7% (Jan 21)

* FY sales of 1,965 million euros ($2.14 billion), up 15.7 pct as reported

BRIEF-Biomerieux affiliate submitted FilmArray Torch to the FDA

* BioFire Diagnostics, LLC, has submitted the FilmArray Torch to the U.S. Food and Drug Administration (FDA) for special 510(k) clearance for use with the FilmArray Respiratory Pane

BRIEF-Biomerieux acquires Applied Maths

* Acquires Applied Maths, a company that develops software solutions for the biosciences, in particular for databasing, analysis and interpretation of complex biological data

BRIEF-Biomerieux and Illumina launch Biomerieux EpiSeq

* Announced on Monday the launch of Biomerieux EpiSeq, an next-generation sequencing (NGS) service for epidemiological monitoring and control of healthcare-associated infections Source text for Eikon: Further company coverage:

BRIEF-Biomerieux introduces molecular diagnostic solution GENE-UP

* Introduces GENE-UP, a new molecular diagnostic solution for food pathogen detection jointly developed with biofire

BRIEF-Biomerieux 9M sales rises to 1,412 million euros

* 9M sales reached 1,412 million euros ($1.60 billion), up 18.3 pct

BRIEF-Biomerieux company Ebola test subject of WHO emergency procedure

* Says its company BioFire Defense, LLC of Salt Lake City, UT announces that its FilmArray Ebola test (BioThreat-E test1) has received Emergency Use Assessment and Listing (EUAL) by the World Health Organization (WHO) allowing the test to be eligible for WHO procurement

BRIEF-Biomerieux H1 operating income rises to 103 million euros

* H1 net income of consolidated companies 59 million euros ($66.42 million) versus 51 million euros a year ago

Select another date:
Search Stocks